FITUSIRAN: payments to doctors
Payments that named FITUSIRAN as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $73K
- Providers
- 9
- Transactions
- 86
- Average per transaction
- $850
The per-transaction average — $850 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 9 providers the average total is $8,125, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Bioverativ Therapeutics Inc. | $73,066 | 99.9% |
| Sanofi-aventis U.S. LLC | $56 | 0.1% |